Zobrazeno 1 - 8
of 8
pro vyhledávání: '"35"'
Autor:
Li-An Xu, Thomas J. Lynch, Lowell L. Hart, Christopher T. Harbison, Christine Horak, Robert C. Hermann, Shaker R. Dakhil, Melissa Awad, Shirin Khambata-Ford, Martin R. Weber
Publikováno v:
Journal of Clinical Oncology. 28:918-927
Purpose The anti–epidermal growth factor receptor (EGFR) antibody cetuximab is efficacious in multiple tumor types. Patient selection with markers predictive of benefit may enhance its therapeutic index. This retrospective, correlative analysis of
Autor:
Suzanne Berlin, Hang Lee, Neil S. Horowitz, Ursula A. Matulonis, Richard T. Penson, Modjulie A. King, Carolyn N. Krasner, Stephen A. Cannistra, Paul DiSilvestro, Don S. Dizon, Maria R. Roche, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 28:154-159
Purpose New strategies are needed to improve outcomes for patients with advanced ovarian cancer. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor but is associated with GI perforations (GI
Autor:
Masato Ozaka, Hiroki Osumi, Keisho Chin, Takashi Ichimura, Tomohiro Matsushima, Hiroyuki Seimiya, Izuma Nakayama, Kensei Yamaguchi, Mitsukuni Suenaga, Tetsuo Mashima, Eiji Shinozaki, Takeru Wakatsuki, Naoya Fujita, Daisuke Takahari, Mariko Ogura
Publikováno v:
Journal of Clinical Oncology. 35:72-72
72 Background: Ramucirumab, anti-VEGFR2 receptor antibody, showed significantly improved survivals of gastric cancer in the second line with paclitaxel or single use; however, no validated biomarker has been available until today. The aim of this stu
Publikováno v:
Journal of Clinical Oncology. 30:e14530-e14530
e14530 Background: This phase II study was performed to evaluate the efficacy and the tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) combined with oral S-1 in gastric cancer patients with macroscopic peritoneal metastasis. We
Autor:
Junichi Sakamoto, Koji Oba, John S. Macdonald, Marc Buyse, Satoshi Morita, Michiya Kobayashi, Shigefumi Yoshino, Yumi Miyashita, Akira Tsuburaya, Kazuhiro Yoshida
Publikováno v:
Journal of Clinical Oncology. 30:72-72
72 Background: Adjuvant chemotherapy with fluoropyrimidine (FP) with or without platinum for gastric cancer (GC) has become standard almost worldwide; however, there has been no comparison among concurrent, sequential, and monotherapy. Paclitaxel (PT
Publikováno v:
Journal of Clinical Oncology. 27:2581-2581
2581 Background: Genexol-PM is a sterile, lyophilized polymeric micellar formulation of paclitaxel which is devoid of Cremophor EL and hence is more tolerable and less toxic. This phase 1 study sought to determine the maximum tolerated dose and the p
Autor:
Charles Lu, J. A. Bankson, V. Valero, Gabriel N. Hortobagyi, Janet E. Price, G. Kiriakova, Roland L. Bassett, Timothy Madden, Nikolaos A. Dallas, Ricardo H. Alvarez
Publikováno v:
Journal of Clinical Oncology. 27:11007-11007
11007 Background: Chemosensitization is the ability to augment the effects of standard chemotherapy. One of the possible mechanisms for chemosensitization is improving intratumoral chemotherapy concentrations by increasing total or regional delivery
Autor:
Mark A. Socinski, E. E. Vokes, Jeffrey A. Bogart, Arthur W. Blackstock, Xiaofei Wang, Julian G. Rosenman, Lin Gu, M. Green
Publikováno v:
Journal of Clinical Oncology. 23:7060-7060
7060 Background: Concurrent CRT is an evidence-based treatment approach for patients with stage III NSCLC. Radiation dose escalation during the CRT may increase local control but be associated with increased toxicity. Single institution trials of ind